Medplus unit faces drug license suspension orders in Karnataka

1 min read     Updated on 15 Jul 2026, 08:15 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received suspension orders for drug licenses at three stores in Karnataka due to violations of the Drugs and Cosmetics Act, 1940. The orders, issued by authorities in Bangalore and Belgaum, result in license suspensions ranging from one to two days. The company estimates a total potential revenue loss of ₹1.59 lakh from these regulatory actions.

powered bylight_fuzz_icon
45672320

*this image is generated using AI for illustrative purposes only.

Optival Health Solutions Private Limited, a subsidiary of medplus health services , has received suspension orders for drug licenses at three of its stores located in Karnataka. The orders were issued by the Assistant Director of the Drugs Control Administration in Bangalore Circle-3 and Belgaum Circle. The company disclosed that the suspensions were imposed due to violations under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The financial impact is estimated at a total potential revenue loss of ₹1.59 lakh.

The first order involves the suspension of the drug license for one day for a store situated at the Sarakki JP Nagar Metro Station. The second order also suspends the license for one day for a store located in Jaraganahalli. Both orders were received from the Bangalore Circle-3 authority. The third order, received from the Belgaum Circle authority, suspends the drug license for two days for a store situated at K C Road Chikkodi.

The following table details the specific actions taken and the estimated financial impact:

Authority Nature of Action Date of Receipt Violation Potential Revenue Loss
Assistant Director, Drugs Control Administration, Bangalore Circle-3, Karnataka Suspension of Drug License for one day (Sarakki JP Nagar Metro Station) 14.07.2026 Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 Rs 0.77 lacs
Assistant Director, Drugs Control Administration, Bangalore Circle-3, Karnataka Suspension of Drug License for one day (Jaraganahalli) - Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 Rs 0.35 lacs
Assistant Director, Drugs Control Administration, Belgaum Circle, Karnataka Suspension of Drug License for two days (K C Road Chikkodi) - Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 Rs 0.47 lacs

The disclosure was made in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Gangadi Madhukar Reddy, Managing Director and Chief Executive Officer of Medplus Health Services Limited. The information is available on the company's website and the exchanges.

Historical Stock Returns for Medplus Health Services

1 Day5 Days1 Month6 Months1 Year5 Years
+0.25%-0.89%-7.09%-2.93%-11.19%-27.85%

Will these regulatory violations trigger increased scrutiny from the Drugs Control Administration on other Medplus outlets?

Does the recurrence of Rule 65 violations indicate a need for systemic changes in the company's compliance training programs?

How might repeated regulatory actions affect investor confidence in Medplus Health Services' operational governance?

Medplus Health Services
View Company Insights
View All News
like19
dislike

MedPlus Subsidiary Receives Drug License Suspension Orders in Karnataka and Andhra Pradesh

1 min read     Updated on 01 Jul 2026, 09:30 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

MedPlus Health Services disclosed that its subsidiary, Optival Health Solutions Private Limited, received multiple drug license suspension orders from the Drugs Control Administration in Hubli, Gadag, and Serilingampally, citing violations under the Drugs and Cosmetics Act, 1940. The suspensions, ranging from one to three days, affect stores in Karnataka and Andhra Pradesh, with a combined potential revenue loss of ₹1.58 lakh. The disclosures were made to BSE and NSE under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

powered bylight_fuzz_icon
43852111

*this image is generated using AI for illustrative purposes only.

MedPlus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, received multiple suspension orders for drug licenses of stores situated in Karnataka and Andhra Pradesh. The regulatory actions, issued by the Drugs Control Administration, cite violations under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The company estimates a total potential revenue loss of ₹1.58 lakh due to these suspensions.

Regulatory Action Details

The subsidiary faced suspension orders from authorities in Hubli, Gadag, and Serilingampally. The orders involve suspensions ranging from one to three days for specific store locations. A recent update on June 30, 2026, detailed additional suspensions in the Gadag circle. The following table summarises the suspension orders and their associated financial impact:

Authority Location Suspension Duration Potential Revenue Loss
Assistant Director, Drugs Control Administration, Hubli Circle, Hubli Karnataka Adarsha Nagar Hubli, Karnataka One day ₹0.22 lacs
Assistant Director, Drugs Control Administration, Gadag Circle, Gadag Karnataka Rani Road Gadag, Karnataka Two days ₹0.60 lacs
Assistant Director, Drugs Control Administration, Gadag Circle, Gadag Karnataka Gajendragad and College Road Gadag, Karnataka One day each ₹0.32 lacs and ₹0.47 lacs respectively
Assistant Director, Drugs Control Administration, Serilingampally Andhra Pradesh Radhakrishna Nagar Attapur Andhra Pradesh Three days ₹0.76 lacs

Key Highlights

  • Optival Health Solutions Private Limited is a subsidiary of MedPlus Health Services.
  • Suspension orders were received under Rule 65 of the Drugs and Cosmetics Act, 1940.
  • The orders impact stores in Hubli and Gadag in Karnataka, and Serilingampally in Andhra Pradesh.
  • The total quantifiable financial impact is a potential revenue loss of ₹1.58 lakh.

The disclosure was made to the BSE Limited and National Stock Exchange of India Limited on June 26, 2026, and June 30, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Medplus Health Services

1 Day5 Days1 Month6 Months1 Year5 Years
+0.25%-0.89%-7.09%-2.93%-11.19%-27.85%

What specific operational changes will MedPlus implement to prevent future regulatory violations in these regions?

Could these suspension orders lead to increased scrutiny from regulators on other MedPlus outlets?

How might this regulatory action affect investor confidence in MedPlus Health Services' compliance standards?

Medplus Health Services
View Company Insights
View All News
like15
dislike

More News on Medplus Health Services

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-11.19%